KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.

C Inagaki, E Oki, K Ando, H Hirano, M Furuta, Y Narita, T Esaki, K Murotani, H Kawakami, K Muro

ESMO Gastrointest Oncol 14 100416

PMID42756594
PMCIDPMC13583981
DOI10.1016/j.esmogo.2026.100416
发表日期2026-09-18
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: Zolbetuximab, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, combined with fluoropyrimidine- and platinum-based chemotherapy, is established as first-line standard of care for patients with CLDN18.2-positive, human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction (GEJ) cancer, based on the phase III SPOTLIGHT and GLOW trials. However, evidence regarding the efficacy and safety of continuing zolbetuximab beyond disease progression remains lacking. Given reports that CLDN18.2 expression is maintained after chemotherapy and the absence of clearly established resistance pathways, continued CLDN18.2-targeted therapy in the second-line setting warrants investigation. AIM: To investigate whether the addition of zolbetuximab to second-line nab-paclitaxel plus ramucirumab improves overall survival (OS) in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma who have progressed with first-line zolbetuximab-based therapy. TRIAL DESIGN: ZELDA (jRCTs071250038) is a multicenter, open-label, randomized phase II (rP2) trial conducted by the West Japan Oncology Group and Kyushu Study Group of Clinical Cancer in Japan. A safety lead-in part (n = 6) confirms the tolerability of the triplet combination (zolbetuximab + nab-paclitaxel + ramucirumab), followed by a rP2 trial (n = 210) with a 1 : 1 allocation to nab-paclitaxel + ramucirumab (arm A, control) or zolbetuximab + nab-paclitaxel + ramucirumab (arm B, experimental). The primary endpoint is OS in the full analysis set. Integrated translational research (ZELDA-TR) is also planned.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。